N Garzorz-Stark1, K Eyerich2. 1. Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, TU München, Biedersteiner Str. 29, 80802, München, Deutschland. natalie.garzorz@tum.de. 2. Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, TU München, Biedersteiner Str. 29, 80802, München, Deutschland.
Abstract
BACKGROUND: For sufficient treatment of patients with chronic inflammatory skin diseases, new concepts need to be established and biomarkers must be identified. OBJECTIVE: Presentation of new markers, their quality and implications for the clinical daily routine. MATERIAL AND METHODS: This article presents a discussion of basic research and a review of current achievements of personalized medicine in the area of chronic inflammatory skin diseases. RESULTS: Promising biomarker for the various entities of chronic inflammatory skin diseases have been proposed; however, they need to be prospectively validated and translated into affordable and feasible tests. CONCLUSION: There is still a long way to go to establish personalized medicine in the field of chronic inflammatory skin diseases and its success is dependent on multicenter collaboration to validate and implement novel biomarkers.
BACKGROUND: For sufficient treatment of patients with chronic inflammatory skin diseases, new concepts need to be established and biomarkers must be identified. OBJECTIVE: Presentation of new markers, their quality and implications for the clinical daily routine. MATERIAL AND METHODS: This article presents a discussion of basic research and a review of current achievements of personalized medicine in the area of chronic inflammatory skin diseases. RESULTS: Promising biomarker for the various entities of chronic inflammatory skin diseases have been proposed; however, they need to be prospectively validated and translated into affordable and feasible tests. CONCLUSION: There is still a long way to go to establish personalized medicine in the field of chronic inflammatory skin diseases and its success is dependent on multicenter collaboration to validate and implement novel biomarkers.
Authors: Patrick A M Jansen; Diana Rodijk-Olthuis; Edward J Hollox; Marijke Kamsteeg; Geuranne S Tjabringa; Gys J de Jongh; Ivonne M J J van Vlijmen-Willems; Judith G M Bergboer; Michelle M van Rossum; Elke M G J de Jong; Martin den Heijer; Andrea W M Evers; Mieke Bergers; John A L Armour; Patrick L J M Zeeuwen; Joost Schalkwijk Journal: PLoS One Date: 2009-03-06 Impact factor: 3.240
Authors: Joerg Wenzel; Bettina Peters; Sabine Zahn; Michael Birth; Kay Hofmann; Daniel Küsters; Stefan Tomiuk; Jens M Baron; Hans F Merk; Cornelia Mauch; Thomas Krieg; Thomas Bieber; Thomas Tüting; Andreas Bosio Journal: J Invest Dermatol Date: 2007-08-16 Impact factor: 8.551